Cardlytics stock holds near recent lows as investors weigh weak revenue and guidance

Cardlytics stock (ISIN US14161W1053) is trading at USD 3.75 on Nasdaq as of September 18, 2026, valuing the company at about USD 22.2 million and leaving the share price close to its recent 52-week lows per data from a US trading portal.

Small-cap valuation and recent price range

According to a stock overview on a US brokerage platform on September 18, 2026, Cardlytics shares changed hands between USD 3.75 and USD 3.90 during that trading day, with the closing price at USD 3.75 on Nasdaq and an intraday trading volume of roughly 20,910 shares, compared with an average daily volume of about 43,030 shares.Robinhood The same portal indicates that at this price level the implied market capitalization stands near USD 22.2 million, underlining how far the company has fallen from earlier years when the stock commanded a significantly higher valuation.

For investors, this narrow trading range close to the low end of recent levels signals a lack of strong buying interest and highlights that Cardlytics now behaves more like a thinly traded micro-cap than the higher-profile ad-tech name it once was. A price of USD 3.75 that sits only marginally above the day’s low of USD 3.75 and roughly 3.8 percent below the intraday high of USD 3.90, as noted in the same overview, shows how limited the intraday upside has been in recent sessions.Robinhood

Recent revenue trends and operating performance

In its most recent quarterly update for the second quarter of 2026, Cardlytics reported that revenue declined compared with the same period a year earlier, reflecting a combination of softer advertising demand on its partner bank platforms and ongoing challenges in monetizing user engagement; the company’s own investor-relations materials for that quarter show year-over-year revenue contraction in the mid-single-digit percent range as management works to stabilize the business.Cardlytics Management indicated in that filing that revenue for the quarter ended June 30, 2026, slipped relative to the prior-year quarter while adjusted losses narrowed modestly thanks to cost controls, but the company remained loss-making.

The same IR communication outlined that Cardlytics continues to prioritize improving ad targeting and measurement, but also acknowledged that near-term growth will be constrained by cautious spending from advertisers and the longer ramp-up time for newer bank partnerships; guidance for the second half of 2026 therefore pointed only to modest sequential revenue improvement from the second quarter level, rather than a sharp rebound, and did not signal a return to strong double-digit growth.Cardlytics This cautious outlook helps explain why the shares, at a market capitalization of around USD 22.2 million as of September 18, 2026, trade at what many investors would see as distressed levels relative to the revenue base.

Analyst stance and key risks

According to a recent compilation of small-cap ad-tech ratings on a financial data portal in mid-September 2026, most covering analysts now maintain neutral or underperform stances on Cardlytics, citing limited visibility on a sustainable return to revenue growth and persistent operating losses despite restructuring efforts; one such overview notes that at least one firm has trimmed its 12-month price target into the mid-single-digit dollar range, effectively in line with where the stock currently trades, after previously modeling a fair value closer to the high-single-digit area for CDLX.Macrotrends

For investors, the main risks around Cardlytics remain concentrated in execution and balance-sheet resilience: continued revenue pressure combined with ongoing losses could force further cost cuts or capital raising, and the very small market capitalization and low daily trading volume as of September 18, 2026, add liquidity risk for those entering or exiting positions in size. On the positive side, any evidence that the company can stabilize revenue and improve margins in upcoming quarterly reports, or secure new bank partnerships that materially expand its user footprint, could provide a catalyst for the stock to move away from the USD 3 to USD 4 range that has prevailed recently.

Stock trades at micro-cap levels

With a closing price of USD 3.75 on Nasdaq as of September 18, 2026, Cardlytics stock stands far below the levels seen in previous years and reflects investor caution about the company’s ability to return to profitable growth; at that price, the implied market capitalization of about USD 22.2 million underscores just how sharply sentiment and valuation have compressed in the face of weaker revenue and cautious guidance.

More news and analyses on Cardlytics stock